Free tool
Drug Trial Radar: Hematology and blood cancers
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
411
Recruiting, industry sponsors, Hematology and blood cancers, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting411
- Completed1,472
411 trials
Showing 1 to 25, recently updated first.
Arvinas Inc.Industry
NCT06393738 · 329 participants (planned) · Start Sep 5, 2024 · Primary completion Dec 2028
Drug: ARV-393; Glofitamab · For: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Sites: New Haven, Connecticut; Miami, Florida; Detroit, Michigan · 28 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04811560 · 494 participants (planned) · Start May 19, 2021 · Primary completion Dec 29, 2028
Drug: Bleximenib · For: Acute Leukemia; Primary Myelofibrosis; Essential Thrombocythemia
Sites: Duarte, California; Orange, California; San Francisco, California · 102 sites in all
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07140016 · 40 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 31, 2029
Drug: gilteritinib · For: Non-small Cell Lung Cancer (NSCLC); Anaplastic Lymphoma Kinase (ALK) Positive
Sites: Fullerton, California; Orange, California; Edwards, Colorado · 17 sites in all
Allterum Therapeutics, IncIndustry
NCT07586618 · 24 participants (planned) · Start Jun 1, 2026 · Primary completion May 2028
Drug: 4A10 · For: Lymphoblastic Lymphoma; Acute Lymphoblastic Leukemia ALL
Sites: Aurora, Colorado; Chicago, Illinois; Indianapolis, Indiana · 9 sites in all
Tethra Biosciences Inc.Industry
NCT05358379 · 330 participants (planned) · Start Apr 14, 2022 · Primary completion Nov 2028
Drug: THT140 · For: Solid Tumor, Adult Lymphoma
Sites: New York, New York; Houston, Texas; Seattle, Washington · 5 sites in all
Cellogen Therapeutics Pvt. Ltd.Industry
NCT07948733 · 18 participants (planned) · Start Oct 26, 2026 · Primary completion Sep 14, 2028
Drug: Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg; Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg and 1 more · For: B-Cell Non-Hodgkin Lymphoma (NHL); B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Vellore, India
- A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT05714839 · 123 participants (planned) · Start Jun 14, 2023 · Primary completion Aug 3, 2028
Drug: Belantamab; Belantamab mafodotin and 2 more · For: Multiple Myeloma
Sites: Bullhead City, Arizona; Los Angeles, California; Pembroke Pines, Florida · 59 sites in all
Immune System Key LtdIndustry
NCT04365179 · 18 participants (planned) · Start Jun 18, 2020 · Primary completion Dec 31, 2027
Drug: Nerofe · For: Advanced MDS; AML
Sites: Miami, Florida
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04910568 · 186 participants (planned) · Start Jul 26, 2021 · Primary completion Dec 21, 2028
Drug: Cevostamab; Tocilizumab and 3 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; Denver, Colorado · 34 sites in all
Enliven TherapeuticsIndustry
NCT05304377 · 250 participants (planned) · Start May 22, 2022 · Primary completion Dec 2027
Drug: ELVN-001 · For: Chronic Myeloid Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Cml
Sites: New York, New York; The Bronx, New York; Portland, Oregon · 45 sites in all
- A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerPivotal-lookingRecruiting
Recursion Pharmaceuticals Inc.Industry
NCT06678659 · 310 participants (planned) · Start Nov 21, 2024 · Primary completion Jul 2029
Drug: REC-1245 · For: Unresectable; Locally Advanced; Metastatic Cancers and 1 more
Sites: Duarte, California; Palo Alto, California; Santa Monica, California · 8 sites in all
PfizerPfizer (PFE)
NCT06703606 · 15 participants (planned) · Start May 13, 2025 · Primary completion May 5, 2027
Drug: MARSTACIMAB · For: Severe Hemophilia A
Sites: La Jolla, California; Los Angeles, California; San Diego, California · 10 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06292780 · 220 participants (planned) · Start Aug 7, 2024 · Primary completion Aug 20, 2028
Drug: Linvoseltamab · For: Relapsed/Refractory Systemic Light Chain Amyloidosis
Sites: Duarte, California; Denver, Colorado; Boston, Massachusetts · 24 sites in all
K36 Therapeutics, Inc.Industry
NCT05651932 · 165 participants (planned) · Start Feb 22, 2023 · Primary completion Dec 31, 2027
Drug: Cohort A1 & A2: KTX-1001; Cohort B1 & B2: KTX-1001+Mezigdomide and 2 more · For: Multiple Myeloma; Myeloma; Myeloma Multiple
Sites: San Francisco, California; Jacksonville, Florida; Miami, Florida · 29 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06379789 · 130 participants (planned) · Start Sep 11, 2024 · Primary completion Aug 14, 2034
Drug: REGV131; LNP1265 · For: Hemophilia B
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 54 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07753148 · 52 participants (planned) · Start Sep 17, 2026 · Primary completion May 5, 2031
Drug: REGN17235 · For: Clonal Cytopenia of Undetermined Significance (CCUS); Low-Risk Myelodysplastic Syndrome (LR-MDS)
Sites: Ghent, Belgium; Roeselare, Belgium; London, United Kingdom
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06768489 · 280 participants (planned) · Start Dec 4, 2024 · Primary completion Jan 2, 2029
Drug: Ramantamig; Daratumumab and 3 more · For: Multiple Myeloma; Smoldering Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis
Sites: Denver, Colorado; Atlanta, Georgia; Clayton, Australia · 16 sites in all
- A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Pivotal-lookingRecruiting
Debiopharm International SAIndustry
NCT06969430 · 154 participants (planned) · Start May 30, 2025 · Primary completion Nov 2031
Drug: Debio 1562M · For: Acute Myeloid Leukemia
Sites: Duarte, California; Tampa, Florida; Chicago, Illinois · 7 sites in all
Incyte CorporationIncyte (INCY)
NCT07853040 · 24 participants (planned) · Start Oct 27, 2026 · Primary completion Mar 31, 2027
Drug: INCB161734 · For: Hepatic Insufficiency; Liver Diseases
Sites: Chandler, Arizona; Orlando, Florida; San Antonio, Texas
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT04643002 · 258 participants (planned) · Start Jan 25, 2021 · Primary completion Sep 13, 2027
Drug: Isatuximab; Dexamethasone and 6 more · For: Plasma Cell Myeloma Refractory
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 28 sites in all
Debiopharm International SAIndustry
NCT05765812 · 116 participants (planned) · Start May 15, 2023 · Primary completion Sep 2028
Drug: Zedoresertib; Temozolomide · For: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype; Astrocytoma, Grade III
Sites: Chicago, Illinois; New York, New York; Dallas, Texas · 16 sites in all
Nurix Therapeutics, Inc.Industry
NCT07520006 · 150 participants (planned) · Start Sep 30, 2026 · Primary completion May 2033
Drug: NX-5948; venetoclax and 2 more · For: B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Irvine, California; Aurora, Colorado; Coral Gables, Florida · 10 sites in all
Umoja BiopharmaIndustry
NCT07735546 · 100 participants (planned) · Start Nov 2026 · Primary completion Dec 31, 2029
Drug: Rapamycin (sirolimus) · For: Multiple Myeloma in Relapse; Multiple Myeloma (MM)
Sites: Westmead, Australia
Autolus LimitedIndustry
NCT06173518 · 30 participants (planned) · Start Nov 16, 2023 · Primary completion Nov 2027
Drug: AUTO1 · For: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 15 sites in all
Incyte Biosciences International SàrlIncyte (INCY)
NCT03934372 · 70 participants (planned) · Start Jan 29, 2020 · Primary completion Feb 1, 2028
Drug: Ponatinib · For: Acute Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blast Phase Chronic Myeloid Leukemia and 6 more
Sites: Ghent, Belgium; Paris, France; Poitiers, France · 23 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.